Pemán

Parasitic Infections in Hematopoietic Stem Cell Transplantation

Isidro Jarque1, Miguel Salavert2 and Javier Pemán3 

1 Hematology Department. Hospital Universitario y Politécnico La Fe, Valencia, Spain.
2 Infectious Diseases Unit. Hospital Universitario y Politécnico La Fe, Valencia, Spain.
3 Microbiology Department. Hospital Universitario y Politécnico La Fe, Valencia, Spain.


Published: July 1, 2016
Received: May 23, 2016
Accepted: June 12, 2016
Mediterr J Hematol Infect Dis 2016, 8(1): e2016035, DOI 10.4084/MJHID.2016.035
This article is available on PDF format at:

This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(
https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Parasitic infections are rarely documented in hematopoietic stem cell transplant recipients. However they may be responsible for fatal complications that are only diagnosed at autopsy. Increased awareness of the possibility of parasitic diseases both in autologous and allogeneic stem cell transplant patients is relevant not only for implementing preventive measures but also for performing an early diagnosis and starting appropriate therapy for these unrecognized but fatal infectious complications in hematopoietic transplant recipients. In this review, we will focus on parasitic diseases occurring in this population especially those with major clinical relevance including toxoplasmosis, American trypanosomiasis, leishmaniasis, malaria, and strongyloidiasis, among others, highlighting the diagnosis and management in hematopoietic transplant recipients.

Introduction

Parasitic diseases continue to have a significant impact on health, quality of life, and economic development wherever they are endemic. In addition, medical advances such as solid organ transplantation compromise the immune system of patients, which render them vulnerable to previously rare opportunistic organisms or to the exacerbation of latent parasitic infections.[1,2]

Parasitic diseases are the most understudied of all infections related to hematopoietic stem cell transplantation (HSCT).[3-5] Parasitic diseases are frequently neglected in this setting in spite of causing life-threatening complications. As a consequence management recommendations in this field are mainly based on expert opinions provided that prospective trials or randomized studies are lacking.

In this review, we will focus on parasitic diseases occurring in HSCT recipients especially those with major clinical relevance (Table 1). A better knowledge of these entities would help to improve prognosis in these potentially fatal complications in which a high level of suspicion could be critical for a proper management.


Table 1 Table 1. Main parasitic diseases in HSCT recipients.

Toxoplasmosis

Toxoplasmosis is a zoonotic illness due to infection with the protozoan Toxoplasma gondii. Although toxoplasmosis occurs worldwide it is more common in patients from endemic regions, including France and the moist tropical areas of Latin America and sub-Saharan Africa, where the prevalence may approach 90%. Risk factors for primary infection include ingestion of cysts in undercooked meat (including beef and lamb) or contaminated soil, contact with oocysts in feline feces, maternal-fetal transmission, or via blood transfusion or transplant from an infected donor.[6] Infection in HSCT recipients can occur through ingestion of contaminated food or water, after receiving an infected allograft, or by reactivation of latent infection.[7-15]

Transplant patients with toxoplasmosis can present with fever, lymphadenopathy, hepatosplenomegaly, meningitis, brain abscess, chorioretinitis, pneumonitis, myocarditis, hepatitis, pancytopenia or disseminated disease. Symptoms often present within 3 months post-transplant but later presentations can be seen, particularly after discontinuation of chemoprophylaxis, or even interruption of the anti-Pneumocystis prophylaxis with cotrimoxazole, which may exert a protective role.

Diagnosis is usually based on the clinical syndrome plus a positive antibody. Definite diagnosis requires the identification of tachyzoites in tissue, or positivity of nucleic acid amplification tests (NAAT) in cerebrospinal fluid (CSF) and/or infected tissues.[16] Multiple ring-enhancing lesions in the basal ganglia or cerebrum on neuroimaging, especially with anti-Toxoplasma IgG seropositivity, is suggestive of central nervous system (CNS) toxoplasmosis and is enough to start treatment. HSCT recipients often show a variable enhancement pattern, with the lesion enhancement inversely correlated with the severity of immunosuppression.[17] Brain biopsy should be considered in non-responding patients, as the radiographic differences with other infections or malignancies are not sufficiently accurate. CSF may have a mild mononuclear pleocytosis and/or an elevated protein. Identification of Toxoplasma DNA by NAAT in CSF has a high specificity (96-100%) but the sensitivity is more limited (52-98%). Rarely tachyzoites can be seen on centrifuged CSF samples after Giemsa staining.

Myocarditis may present with heart failure and diagnosis is made by seeing tachyzoites on myocardial biopsy. Chorioretinitis often presents with scotoma, blurred vision, pain or photophobia. Raised, yellow-white, cottony lesions in a nonvascular distribution (unlike the perivascular exudates of CMV retinitis) are seen and vitreal inflammation may be present on fundoscopic examination. The pulmonary disease often presents with fever, dyspnea, cough, and reticulonodular infiltrates on chest imaging. This pattern of disease may be indistinguishable from Pneumocystis jirovecii pneumonia but T. gondii tachyzoites are identified in the bronchoalveolar lavage (BAL) fluid. Serum levels of lactate dehidrogenase (LDH), unlike P. jirovecii pneumonia, may be extremely high (above 1000 U/L). Although rare, cutaneous toxoplasmosis has been reported after HSCT.[18]

Treatment for active toxoplasmosis includes induction therapy with pyrimethamine (200 mg po x1 dose, then 75 mg/day po) (plus folinic acid) and sulfadiazine (1 g if <60 kg; 1.5 g if >=60 kg po, q6h) plus folinic acid (10-25 mg/day po). Induction therapy is usually given for at least six weeks depending on the response to treatment. In case of allergy or intolerance to sulfadiazine, it can be used clindamycin (600-900 mg q6h) (Table 2).


Table 2 Table 2. Recommended treatment for parasitic infections in HSCT recipients.

In case of worsening of clinical symptoms or brain imaging following an initial improvement after 14-21 days of treatment, it should be considered a possible diagnosis of the immune-reconstitution inflammatory syndrome (IRIS), and practice of a puncture or biopsy of the lesion to rule out other etiologies aside from the CNS toxoplasmosis.

Induction therapy should be followed by chronic suppressive therapy (secondary prophylaxis) to eradicate the encysted form of the parasite and prevent recrudescence of disease. Chronic suppressive therapy with reduced toxicity medication, such as cotrimoxazole may be considered.[19]

The routine use of cotrimoxazole for post-HSCT prophylaxis has decreased the risk of toxoplasmosis and is currently the routine prophylaxis against this parasite. Multiple studies support the efficacy of primary prophylaxis with cotrimoxazole, although the optimal dose and duration of cotrimoxazole remain unclear. Many studies showed successful prophylaxis using cotrimoxazole (160 mg of trimethoprim, 800 mg of sulfamethoxazole) thrice weekly for varying durations (range 3 months to lifelong). In patients with HIV/AIDS, cotrimoxazole one tablet daily is recommended as first line prophylaxis. An alternative to cotrimoxazole is dapsone plus pyrimethamine (plus folinic acid). Atovaquone with or without pyrimethamine (plus folinic acid) has not been well studied but is also considered a likely effective alternative regimen.

Other possible alternatives in immunocompromised hosts included combination of pyrimethamine (and folinic acid) with atovaquone, clarithromycin, azithromycin or dapsone. Folinic acid must be added to all regimens containing pyrimethamine, can be raised  the dose to 50 mg/day in case of myelotoxicity by pyrimethamine.

To avoid primary infection, transplant recipients should avoid contact with undercooked meat, soil, water or animal feces that might contain T. gondii cysts.

Chagas disease (American trypanosomiasis)

Chagas disease is caused by the protozoan Trypanosoma cruzi and infection is transmitted to humans in Latin America by inoculation of infected feces from triatomine bugs.[20] However, T. cruzi infection can also be transmitted via blood transfusion, infected mother to fetus, oral ingestion, or transplantation. Chagas disease is endemic in most Latin-American countries where 8-9 million people are currently living with infection and 2-5 million people have chagasic cardiomyopathy.

In the last decades, increasing international migration and travel from Latin America to Europe have favored the emergence of Chagas disease outside its traditional boundaries. In the absence of the vector, one of the potential modes of transmission of Chagas disease in non-endemic regions is through blood and blood products. As a consequence cases of Chagas disease have been reported in HSCT recipients.[21-24]

Human disease has two distinct phases: the acute phase and the chronic infection. In the normal host, the acute illness (a febrile syndrome with lymphadenopathy and hepatosplenomegaly) usually resolves spontaneously even if untreated. However, without specific treatment, the infection persists in spite of strong evidence of immunity and patients become chronically infected with the parasite. The phase of clinical latency can last 10-30 years or lifelong and approximately 30% of patients will develop an irreversible disease in heart (27%), esophagus and colon (6%) and peripheral nervous system (3%). T. cruzi seronegative recipients of seropositive donors might develop an acute infection after transplantation. Clinical manifestations can include fever, malaise, anorexia, hepatosplenomegaly and acute myocarditis with a mean time to symptom onset of 112 days (range 23–240 days).[25]

Diagnosis of chronic infection is made by detection of antibodies to T. cruzi antigens, most commonly by enzyme immunoassay (EIA) or immunofluorescence immunoassay (IFA) methods. No single test has sufficient sensitivity or specificity to be relied on alone for clinical diagnosis. Therefore, two serological tests based on different antigens and/or techniques should be used to increase the accuracy of the diagnosis. When discordant testing occurs, a third test should be employed.

In transplant recipients with acute infection and those with chronic T. cruzi infection where there is a concern for reactivation, serological testing has limited utility. Direct parasitological test methods for diagnosis include microscopy of the fresh buffy coat preparations, Giemsa-stained peripheral blood smears, and NAAT of whole blood or tissue from a biopsy. PCR techniques provide the most sensitive testing and can often identify positive results days to weeks before circulating trypomastigotes are detectable by microscopy of peripheral blood smear and buffy coat preparations. Patients with chronic T. cruzi infection may have positive NAAT in blood in the absence of disease reactivation and may not be helpful.

Monitoring for infection after transplant from a seropositive donor to a seronegative recipient and after transplantation in a recipient with chronic T. cruzi infection is recommended so that treatment can be initiated before the development of clinically significant disease. Monitoring can be accomplished by NAAT of blood for T. cruzi (when available) and review of peripheral blood for parasitemia weekly for 2 months post-transplant, every two weeks for the third month, then monthly afterwards for a period to be determined by the specific clinical scenario (intensified immunosuppression, unexplained fever, graft versus host disease).

Treatment is recommended for patients with evidence of reactivation of chronic infection or acute infection post-transplantation. Two drugs are available for treatment of Chagas disease, nifurtimox and benznidazole.[26,27] Both drugs have significant toxicity: benznidazole is frequently associated with rash and a dose-dependent peripheral neuropathy while nifurtimox is associated with gastrointestinal (anorexia, weight loss, nausea) and CNS (irritability, insomnia, tremors) symptoms. Benznidazole (5-7 mg/kg/day po bid x 60 days) is better tolerated among transplant recipients and has fewer drug interactions when compared to nifurtimox and therefore, benznidazole is generally preferred for first-line treatment (Table 2). Posaconazole has shown anti-Trypanosoma activity in patients with chronic Chagas disease. However, in a randomized clinical trial to assess the efficacy and safety of posaconazole versus benznidazole administered for 60 days in immunocompetent adults with chronic T. cruzi infection, significantly more patients in the posaconazole group had treatment failure during follow-up (higher rate of relapse). The role of this antifungal agent with anti-Trypanosoma activity in immunosuppressed patients is unknown at present.[28]

Prophylactic therapy in asymptomatic patients is not recommended and preemptive monitoring with NAAT and peripheral smear are preferred to determine the need for treatment. Confirmation of infection (or its absence) has significant implications for long-term management. 


Leishmaniasis

Leishmaniasis is caused by a heterogeneous group of protozoan parasites belonging to the genus Leishmania and presents with a variety of different clinical syndromes. The infection is acquired primarily through the bite of an infected female sandfly (genus Phlebotomus or Lutzomyia). Occasionally the disease is transmitted by transfusion, transplantation or, in drug addict patients, by sharing contaminated needles or syringes. It is also possible maternal-fetal vertical transmission. It is estimated that 350 million people are at risk of acquiring the infection and that 12 million may be infected. Leishmaniasis is found in tropical and subtropical climates and is endemic in the Mediterranean Basin countries. The disease may appear as late as 30 years after the initial infection. Therefore, even a distant exposure needs to be considered for differential diagnosis.
Derangement of host cellular immunity is a significant risk factor for the development of symptomatic and severe infections and for increased mortality in patients with leishmaniasis. Leishmaniasis is the paradigm of imbalance between the immune responses of type Th1 / Th2 and Th17 / Treg, with functional disruption of granuloma. In most immunocompetent hosts, the Leishmania spp. infection is asymptomatic; however, viable organisms remain latent for the life of the host. The main potential mechanisms of acquisition in transplant recipients are a primary infection or reactivation of latent infection, both after transplantation. 
Clinical manifestations of disease vary based on the infecting organism and host immune response. Visceral leishmaniasis is caused by L. donovani complex (L. donovani, L. infantum and L. chagasi) and the clinical features are similar to those of immunocompetent patients. Patients suffer from fever, hepatosplenomegaly and pancytopenia. Median time to onset was 30 days post-transplant (range, 7 days to 5 months) but reactivations as far as 55 and 96 months posttransplantation have been reported.[29] Information about HSCT patients is limited mainly to case reports.[30-35]
Microscopic examination of Giemsa stained bone marrow aspirate/biopsy (Figure 1),[36] splenic aspirate, culture in special media (NNN and others) and NAAT are the gold standards for diagnosis of visceral leishmaniasis. Occasionally the diagnosis can be made from a biopsy of other tissues such as lymph node, liver or intestine, or by means of fine needle spleen puncture. Serological testing for visceral leishmaniasis is highly sensitive in transplant recipients but serology cannot distinguish between prior exposure and active infection and may cross-react with other protozoa. Urinary antigen detection shows high sensitivity but poor specifity for the diagnosis of visceral leishmaniasis.[37]


Figure 1 Figure 1. Leishmania infantum in bone marrow smears. A: Macrophage containing amastigote forms (Leishman-Donovan bodies). B: Apparently extracellular parasites  (May-Grünwald-Giemsa staining 600X)  
 

Drugs with efficacy in the treatment of visceral leishmaniasis include amphotericin B, pentavalent antimony, paromomycin, and miltefosine but liposomal amphotericin B (3 mg/Kg IV once daily, days 1-5 and days 14, 21) has been shown to be the most efficacious treatment for this disease in immunocompetent patients.[38] In immunocompromised hosts (Table 2) the FDA approved regimen is liposomal amphotericin B 4 mg/kg daily on days 1-5, 10, 17, 24, 31 and 38 (total of 40 mg/kg).[39] Cure rates with liposomal amphotericin B in immunocompromised patients approach the same success seen in immune competent hosts. Miltefosine (2,5 mg/kg/day, maximum daily dose of 150 mg) is an oral treatment option in case of amphotericin B intolerance or toxicity. Secondary prophylaxis with intermittent dosing of this drug, every 3 to 4 weeks as in AIDS, may be useful for preventing relapse. Tested combinations (of amphotericin B and miltefosine) may allow shortening the duration of treatment. In refractory cases, with no response or frequent relapses due to major problems of cellular immunity, it has tested the addition of interferon-gamma with varying results, but this option can involve risks in transplant patients.

Data are lacking to determine if screening potential transplant recipients for visceral leishmaniasis would be beneficial. However, those known to be seropositive at the time of transplant should be monitored closely for signs and symptoms of reactivation of infection. Given the limited data on potential donor-derived infection, donor screening cannot be recommended.


Malaria

Malaria represents an immense health problem in developing countries where it is the cause of more than 300 million acute cases and over 1 million deaths per year. It is transmitted to humans mostly through the bite of the female Anopheles mosquito. Blood transfusions and organ transplantation are responsible for some cases in endemic areas and occasionally in countries with large immigrant populations. The disease does not produce protective immunity, but some degree of resistance to clinically severe hyperinfection is achieved through successive exposure and through the persistence of plasmodia in the liver, the microvasculature and the blood stream. This incomplete acquired immunity is unable to eradicate the infection completely but explains the lack of detectable parasitemia and the higher incidence of asymptomatic disease in adults from endemic regions. This poses a problem at the time of blood or organ donation when the epidemiological background is not appropriately investigated.

Many cases of malaria have been described in transplant recipients. In developed countries the disease is seldom seen but it should be considered when caring for a transplanted patient who has resided or visited areas where the disease is endemic (or has received a transplant from a donor who has been in endemic areas) and presents with an unexplained febrile illness. The four different main plasmodia species that infect humans, Plasmodium ovale, P. vivax, P. malariae and P. falciparum, have all been diagnosed in transplant recipients. Fever is the most frequent presenting symptom, but it has not always the typical paroxysmal or cyclic pattern. The main risk in immunosuppressed patients is the development of severe forms of malaria, with multiple organ failure (respiratory distress syndrome, cardiomyopathy, renal and liver failure, etc.) or involvement of CNS.

Malaria is classically diagnosed by microscopic observation of Giemsa stained thick and thin blood smears with the determination of percent parasitemia. Rapid diagnostic tests are available by using dipsticks and allow the detection of specific plasmodia antigens in clinically significant malarial infections. Alternative diagnostic techniques that are recommended in some circumstances to screen blood donors include antigen detection immunochromatographic assay (a rapid diagnostic test); immunofluorescent-assay techniques for species-specific enzymes and NAAT. In most post-transplant cases, the diagnosis was made by the identification of the parasite in blood smears in febrile patients with unexplained hemolysis and thrombocytopenia.

Specific treatment of malaria relies on the use of anti-Plasmodium drugs. The identification of plasmodia species, the knowledge of their geographical distribution and their susceptibility patterns are essential. P. vivax, P. malariae, P. ovale and uncomplicated P. falciparum infection in chloroquine-susceptible regions should be treated with chloroquine phosphate (1 g -600 mg base- po, them 0.5 g in 6 h, then 0.5 g daily x 2 days; total 2500 mg) or hydroxychloroquine (800 mg salt -620 mg base- po, followed by 400 mg salt po at 6, 24, 48 h; total: 2000 mg salt). However, resistance to chloroquine has been described from Oceania for P. vivax. Uncomplicated P. falciparum infection acquired in a chloroquine resistant region can be treated with an artemisinin combination therapy (artemether-lumefantrine 4 tablets -80 mg/480 mg- as a single dose, then 4 tablets again after 8 h, then 4 tablets every 12 h for 2 days), atovaquone-proguanil (4 tablets -1000 mg/400 mg- po in a single dose daily x 3 days), quinine-based regimen (quinine sulfate 650 mg pot id x 3 days, plus doxycycline 100 mg po bid), or mefloquine (750 mg po x 1 dose, then 500 mg po x 1 dose 6-12 h later). Severe cases of P. falciparum infection should be treated with intravenous artesunate followed by doxycycline, atovaquone-proguanil or mefloquine (Table 2). When artesunate is not available, intravenous quinine or quinidine plus doxycycline, tetracycline or clindamycin should be given. Primaquine phosphate (2 tablets po once daily x 14 days) should be used to prevent relapse of P. vivax and P. ovale (after rule out G6PD deficiency).

Malaria is potentially fatal in the transplant recipient. Early diagnosis and conventional specific treatment usually result in prompt and uneventful recovery. P. falciparum infection, drug toxicity and other infections may hamper the outcome. Special attention is needed when quinine is used for treatment because it may interfere with cyclosporine metabolism, decreasing its blood levels.

Screening of donors who have recently spent time (preceding 3 years) in malarious regions should be considered. Potential screening methods should include thick and thin smear stained with Giemsa. Rapid diagnostic tests detecting the HRP2 antigen can also be taken into consideration when an expert review of thick and thin smears is not available. Recipients traveling to endemic regions should be given appropriate chemoprophylaxis to prevent infection during travel. Chloroquine can potentiate levels of cyclosporine and appropriate dose adjustments should be made.


Babesiosis

Babesiosis is a tick-borne, zoonotic protozoal illness that occurs after infection with Babesia spp., which invades and lyses red blood cells. Several species cause human disease and include Babesia divergens in Europe and B. microti in the USA. B. divergens appears to be more virulent than others. Transmission to humans occurs via ticks of the Ixodes genus or rarely through blood transfusion. There have been reports of concurrent transmission of infection with Babesia and Borrelia burgdorferi (Lyme disease agent) to the same host (usually an immunocompetent host), since the vector is the same tick.

Risk factors for severe babesiosis include anatomic or functional asplenia, immunocompromised state, rituximab use, thrombocytopenia, parasitemia >10%, and older age (>60 years). Only two cases have been reported to date after HSCT.[40,41] Clinical manifestations range from asymptomatic to life threatening disease. Early symptoms may be fever and malaise, which can progress to severe hemolytic anemia (potentially manifesting as a posttransplant hemolytic-uremic or hemophagocytic syndromes), adult respiratory distress syndrome, multi-organ  failure and even death. Blood tests may show hemolytic anemia, thrombocytopenia and conjugated hyperbilirubinemia. Disease severity correlates with the degree of parasitemia, as in malaria.

Babesiosis can be diagnosed by direct microscopic visual review of peripheral blood smear or by NAAT of blood. Diagnostic confusion between Plasmodium spp. (malaria) and Babesia spp. can occur due to the similarity in morphology on microscopy when infecting red blood cells. Specific epidemiologic exposures and NAAT can aid in differentiating the diseases. For babesiosis bone marrow biopsy may reveal hemophagocytosis and marrow histiocytosis.

Babesiosis is a potentially life threatening infection in immunocompromised hosts and antimicrobial treatment should begin immediately. Exchange transfusion should be considered in cases of greater than 10% parasitemia, severe hemolysis, severe renal and/or hepatic and/or pulmonary involvement.[42] Reduction in immunosuppressive regimen should be considered. Atovaquone (750 mg po q 12 h) plus azithromycin (500-1000 mg po on day 1, then 250-1000 mg/day po) for a total of 7-10 days can be used in those able to take oral medications (Table 2). Clindamycin (300 mg-600 mg iv qid x 7 days) plus quinine (650 mg po tid x 7-10 days) plus exchange transfusion (if >10% parasitemia) is recommended in severe cases. In a prospective, nonblinded, randomized trial of the two regimens in 58 normal hosts, atovaquone and azithromycin were as effective as clindamycin and quinine with fewer adverse reactions (15% vs. 72%). The most common adverse effects with atovaquone and azithromycin were diarrhea and rash (8% each), while clindamycin and quinine common adverse effects were tinnitus (39%), diarrhea (33%) and decreased hearing (28%). Azithromycin may increase the serum concentration of tacrolimus and patients should be monitored for toxicity. Sirolimus and tacrolimus metabolism may be slowed by the CYP3A4 inhibitor quinidine.

The optimal antimicrobial or combination therapy in transplant recipients is not clear; persistent relapsing illness has been well described in other immunocompromised hosts. In a series of 14 immunocompromised subjects, most with B-cell lymphoma, asplenic or treated with rituximab, anti-Babesia treatment was required for at least 6 weeks to achieve a cure. Resolution of persistent infection occurred in 11 patients when antibiotic treatment was continued ≥ 2 weeks after documenting negative blood smears. Three (21%) subjects died, highlighting the severity of disease in this population and the need for longer treatment and prolonged monitoring compared to normal hosts.[43] Though rare, resistance to the atovaquone/azithromycin regimen can occur, more commonly in immunocompromised hosts.[44] Blood smears should be used for monitoring response to therapy and for relapse after completion of treatment, NAAT can be considered when available.

When visiting endemic areas, transplant recipients should avoid tick exposure by using permethrin repellants on clothing, DEET or picaridin repellants on skin, and general protective clothing.[45] Frequent tick checks and prompt removal is valuable, because early removal decreases the chance of transmission.

Prospective living donors should avoid high-risk exposures in endemic regions in the weeks prior to donation. Living donors with a prior diagnosis of Babesia infection should report this and document they are clear of infection prior to donation.


Amebic Meningoencephalitis

Acanthamoeba are protozoan parasites found in dust, soil, water, contact lens fluid, air conditioners, sewage, and may colonize the nose and throats of healthy individuals. Acanthamoeba can cause either focal disease (usually keratitis, granulomatous amebic encephalitis, brain abscess, pulmonary lesions, cutaneous lesions, or sinusitis) or disseminated acanthamebiasis that is often fatal in transplant recipients (Figure 2).[46-52]


Figure 2
Figure 2. Histopathological observation of the brain tissue biopsy specimen showing Acanthamoeba trophozoite (A) and cysts (B, C, D) (hematoxylin-eosin staining); D: Nomarski differential interference contrast microscopy; n: nucleus; scale bars:A,C,D,10lm;B=20lm). 



Naegleria are ameba found in warm fresh water, heated contaminated tap-water, and soil. Infection can occur from exposition to contaminated water by swimming or by nasal sinus irrigation.

Diagnosis is made by identifying cysts or trophozoites in infected tissue. Cutaneous lesions may be the initial manifestation of infection and should be biopsied as early diagnosis is imperative to optimize the chance of survival. A direct examination of CSF should also be performed. Acanthamoeba can be cultured on agar plates coated with Gram-negative bacteria; it may take up to two weeks of culture before the amebas appear as track marks within the bacterial growth. Immunofluorescent tests may be used for species confirmation; DNA and RNA probes can also be used, but are not widely available. Serology is only useful for seroprevalence studies but not for diagnosis.

Optimal treatment regimens for Acanthamoeba infections remain unknown (Table 2). Drug sensitivities of free-living amebic infections differ between genera, species, and strains. Combinations of amphotericin B products with rifampin or imidazoles have been tried, as have combinations of sulfonamide antibiotics, azithromycin, miltefosine, caspofungin and flucytosine. Pentamidine has some in vitro activity. While some drugs are effective in vitro against Naegleria, nearly all infections are fatal. Prevention is the most important defense against this infection at the moment.

How best to prevent the rare infections due to Acanthamoeba is not clear, as the amoeba are fairly ubiquitous and seroprevalance rates are high. Cotrimoxazole has been used in treatment regimens; it is not known whether its common use in prophylaxis may be able to prevent infections. Naegleria prevention includes avoiding exposure. If nasal sinus irrigation is necessary, use boiled water, filtered (≤1 µm) water, or distilled/sterile water.


Intestinal Parasitosis

Intestinal parasitic infections are prevalent in developing regions of the world. Accordingly, with increasing travel to and from endemic regions, intestinal parasites may have an increasingly significant role in transplantation. Moreover, relevant parasites including Strongyloides, Giardia, Cryptosporidium and Entamoeba have a worldwide distribution. A careful pretransplant social history can identify at-risk individuals who may benefit from focused screening for persistent parasitic infection. Intestinal parasitic infections are often asymptomatic before transplantation but flourish under immunosuppression, becoming clinically evident. Eosinophilia, gastroenteritis and other clinical manifestations of parasite infections prior to transplant should also trigger an appropriate workup.

Intestinal protozoa.

Cryptosporidium, Cystoisospora belli, Cyclospora, Microsporidia, Blastocystis hominis and Giardia can all cause significant, and sometimes protracted, gastroenteritis in transplant recipients.[53] Transmission is more common in the developing world, with rates of infection as high as 20%, and can occur from contaminated food and water, person-to- person spread and zoonotic exposures. Cryptosporidium transmission in the developed world is facilitated by chlorine resistant oocytes and the 3-7 µm diameter of Cryptosporidium that can bypass many municipal water filtration and treatment systems. Moreover, infected individuals produce up to 100 million oocysts per day, while as few as 10-30 oocysts may cause infection in healthy persons.

Standard examination for ova and parasites in feces may be helpful but are time consuming. The concentration of stool and subsequent special stains may be more sensitive for certain pathogens; many laboratories use a modified trichrome stain or chromotrope 2R to diagnose microsporidial infections and modified acid fast stain for Cyclospora. EIA of stool may help rapidly diagnose Cryptosporidium and Giardia. Direct immunofluorescence tests for Giardia and Cryptosporidium are also available. NAAT may also be helpful when available. Electron microscopy of bowel biopsies may also be useful in diagnosing these infections and for Microsporidia species identification.

Intestinal protozoa infections are primarily acquired from contaminated food and water. Transplant recipients should avoid untreated well or lake water, and preferentially drink treated municipal water or bottled water. There are no data to support the use of bottled water over treated municipal water for transplant recipients. Person-to-person and zoonotic transmission can occur; transplant recipients should be aware of the potential risks.

The treatment of choice for intestinal parasitic infections in HSCT recipients is summarized in Table 2.

Strongyloidiasis is a parasitic disease caused by the nematode Strongyloides stercoralis that enter the body through exposed skin, such as bare feet. Strongyloidiasis is most common in tropical or subtropical climates and most people who are infected with S. stercoralis do not know they are infected and have no symptoms. Others may develop a severe form and, if untreated, become critically ill and potentially die. S. stercoralis infects approximately 100 million persons worldwide. The parasite is endemic in the tropics and subtropics, and has been reported from temperate areas such as Southern Europe. Strongyloides is found more frequently in the socioeconomically disadvantaged, in institutionalized populations, and in rural areas. It is often associated with agricultural activities. The most common way of becoming infected with Strongyloides is by contacting soil that is contaminated with Strongyloides larvae. S. stercoralis is able to complete its life cycle both in the environment and in the human host. As a consequence, the parasite has an auto-infective cycle that produces long-term persistent infections. The rate of autoinfection is regulated by the immune response of the host and the severity of the disease correlates with worm burden. The major reservoir of the parasite is soil contaminated with human feces that harbor Strongyloides larvae. The filariform larvae penetrate the intact skin, enter the circulatory system, migrate to the lung, penetrate alveolar spaces, and move to the pharynx/trachea where swallowing allows access to the duodenal mucosa where they become adult parasites. Significant tissue phases of the life cycle accentuate blood eosinophilia. Adult females reproduce asexually (parthenogenesis) and sexually, laying eggs that become either rhabditiform larvae (which are eliminated with the stools completing the parasite life cycle), or filariform larvae that penetrate intestinal mucosa and perpetuate the infection. The molting of rhabditiform larvae into filariform larvae is accelerated under immunosuppression, allowing a massive number of larvae from the intestinal lumen or the perianal skin to autoreinfect the host. As a result, a high number of adult worms are found in the intestinal lumen. This can lead to lung involvement or the disseminated form of the disease.

Clinical presentation and outcomes depend on the interaction between the parasite and the host immune response, especially the Th-2 cell-mediated immunity. Some clinical conditions associated with defects in cell-mediated immunity can modify an asymptomatic intestinal carriage into a fulminant and frequently fatal disease.

Clinical syndromes include acute infection; chronic infection with parasite persistence and autoinfection manifested as localized gastrointestinal, cutaneous (larva currens) or pulmonary syndromes; hyperinfection syndrome (HIS) and disseminated disease (DD). HIS is characterized by accelerated larvae production, migration and elevated parasite burden with evident clinical manifestations, the larvae being restricted to pulmonary and gastrointestinal systems. DD includes the components of HIS with additional larva spread to other organs.[54] Risk factors for HIS and DD have been linked to the immune status of the host and are mainly related to corticosteroids, anti-TNF agents, cytotoxic drugs or other immunosuppressive agents. Hypogammaglobulinemia and HTLV-I co-infection are also known risk factors for progression to HIS and DD.

Strongyloidiasis can be a devastating disease in transplant recipients; the mortality rate approaches 50% in HIS and 70% in DD. The clinical disease may present with pulmonary involvement, bacterial sepsis or bacterial meningitis with Gram-negative rods from intestinal flora carried on the surface of the parasite during tissue migration. Gastrointestinal presentations include acute and severe abdominal disease, bloody diarrhea, adynamic ileus, intestinal obstruction, and gastrointestinal hemorrhage, caused by larval damage inflicted as they penetrate through the gut wall. S. stercoralis HIS has been reported in recipients of HSCT, associated with high mortality rates.[55-57] The risk is increased in allogeneic transplants in comparison with the autologous HSCT. In these patients, HS appears in the immediate post-transplantation period, when immunosuppression is most intense. [58,59]

Eosinophilia can be found in patients with Strongyloides acute infection. However, patients with chronic infection, HIS, DD and immunocompromised patients may have normal eosinophil counts, even eosinopenia. The absence of eosinophilia does not rule out disease in recipient or donors.[60] Definite diagnosis is achieved by identification of larvae by microscopic wet mount examination of liquid samples (mainly stool or duodenal aspirate) (Figure 3). Typically only HIS/DD have enough larvae to allow detection consistently.[61] However, in the course of the DD larvae can be found in respiratory secretions, CSF, peritoneal fluid, urine, pleural effusion, blood and other tissue specimens. Larvae are often accidentally found when searching for other pathogens as causes of the severe disease. In uncomplicated cases, stool larvae density is low and elimination intermittent (direct observation sensitivity 0-14%). Duodenal fluid aspirate, while more sensitive than direct stool examination has only 76% sensitivity and involves an invasive procedure.


Figure 3
Figure 3. Rhabditiform larvae of  Strongyloides stercoralis in stool (Wet mount 400X)    

Serological testing is often more sensitive for diagnosis of infection, although cannot distinguish active and prior infection, and may not be available worldwide. Enzyme-linked immunosorbent assay (EIA) is highly sensitive (80-95%) and specific (90%) in normal hosts. In immunocompromised patients sensitivity is reduced to 68%, with retained specificity at 89%.[62] False-positive results are mostly related to the presence of other helminthic infections; thus, local epidemiology is important when considering the positive predictive value. A gelatin particle indirect agglutination (GPIA) has 98% sensitivity and 100% specificity.

Ivermectin (200 µg/kg/day po x 2 days) is the treatment of choice for strongyloidiasis and is effective at eradicating adult parasites and larvae from the intestine in normal hosts with intestinal disease (Table 2). A repeated dose at two weeks is designed to treat the less susceptible forms by life cycle stage. Adverse effects are infrequent and usually mild. Albendazole (400 mg po bid x 7 days) has a primary cure rate of only 45–75% making it a second-line therapy. Thiabendazole, is the agent with the most clinical experience, although the least satisfactory of all available drugs, due to frequent relapses and toxicities.

The experience with ivermectin for the treatment of HIS or DD in transplant recipients is limited. Cases with heavy parasitic burden require daily doses until clearance; with additional doses for 7-14 days to reduce the risk of relapse. Anecdotal experiences lead some to advocate combination or sequential ivermectin and albendazole treatment. Severe strongyloidiasis with concomitant malabsorption is a serious challenge to oral treatment. Off-label rectal ivermectin can be effective in patients unable to tolerate or absorb oral therapy.[63] A parenteral veterinary formulation of ivermectin has been used subcutaneously with some success.[64]

Transplant recipients should be educated to wear closed footwear in endemic environments to reduce the risk of primary infection. To mitigate the risk of disseminated strongyloidiasis in asymptomatic or paucisymptomatic patients, expanded screening with a detailed history, parasitological studies and serology facilitate necessary treatment of infection before transplantation is needed. In addition to asking about international travel, it is important to inquire about work, volunteer, or military service abroad which many patients do not consider “travel.” If not feasible, consider empiric treatment before initiation of immunosuppressive therapy for transplant candidates with unexplained eosinophilia, a history of parasitic infection and/or residence in or travel to, endemic areas even in the remote past.

Evaluation for latent strongyloidiasis should be strongly considered in transplant candidates with epidemiological risk factors or unexplained eosinophilia during pretransplant evaluation.

References

  1. Martín-Dávila P, Fortún J, López-Vélez R et al. Transmission of tropical and geographically restricted infections during solid-organ transplantation. Clin Microbiol Rev 2008;21:60-96. http://dx.doi.org/10.1128/CMR.00021-07 PMid:18202437 PMCid:PMC2223841       
  2. Schwartz BS, Mawhorter SD; AST Infectious Diseases Community of Practice. Parasitic infections in solid organ transplantation. Am J Transplant 2013;13 (Suppl 4):280-303. http://dx.doi.org/10.1111/ajt.12120 PMid:23465021           
  3. Saavedra S, Jarque I, Sanz GF et al. Infectious complications in patients undergoing unrelated donor bone marrow transplantation: experience from a single institution. Clin Microbiol Infect 2002;8:725-733. http://dx.doi.org/10.1046/j.1469-0691.2002.00458.x PMid:12445010           
  4. Parody R, Martino R, Rovira M et al. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol Blood Marrow Transplant 2006;12:734-748. http://dx.doi.org/10.1016/j.bbmt.2006.03.007 PMid:16785063           
  5. Cahu X, Rialland F, Touzeau C et al. Infectious complications after unrelated umbilical cord blood transplantation in adult patients with hematologic malignancies. Biol Blood Marrow Transplant 2009;15:1531-1537. http://dx.doi.org/10.1016/j.bbmt.2009.07.021 PMid:19896076           
  6. Kotton CN. Zoonoses in solid-organ and hematopoietic stem cell transplant recipients. Clin Infect Dis 2007; 44: 857-866. http://dx.doi.org/10.1086/511859 PMid:17304461           
  7. Martino R, Maertens J, Bretagne S et al. Toxoplasmosis after hematopoietic stem cell transplantation. Clin Infect Dis 2000;31:1188-1195. http://dx.doi.org/10.1086/317471 PMid:11073751           
  8. López-Duarte M, Insunza A, Conde E, Iriondo A, Mazorra F, Zubizarreta A. Cerebral toxoplasmosis after autologous peripheral blood stem cell transplantation. Eur J Clin Microbiol Infect Dis 2003;22:548-550. http://dx.doi.org/10.1007/s10096-003-0983-6 PMid:12942340           
  9. Power M, Vandenberghe E, Conneally E et al. Retinal and cerebral toxoplasmosis following nonmyeloablative stem cell transplant for chronic lymphocytic leukaemia. Bone Marrow Transplant 2005;36:1019-1020. http://dx.doi.org/10.1038/sj.bmt.1705177 PMid:16205728           
  10. Goebel WS, Conway JH, Faught P, Vakili ST, Haut PR. Disseminated toxoplasmosis resulting in graft failure in a cord blood stem cell transplant recipient. Pediatr Blood Cancer 2007;48:222-226. http://dx.doi.org/10.1002/pbc.20537 PMid:16333839           
  11. Duband S, Cornillon J, Tavernier E, Dumollard JM, Guyotat D, Péoc'h M. Toxoplasmosis with hemophagocytic syndrome after bone marrow transplantation: diagnosis at autopsy. Transpl Infect Dis 2008;10:372-374. http://dx.doi.org/10.1111/j.1399-3062.2008.00310.x PMid:18384483           
  12. Edvinsson B, Lundquist J, Ljungman P, Ringdén O, Evengård B. A prospective study of diagnosis of Toxoplasma gondii infection after bone marrow transplantation. APMIS 2008;116:345-351. http://dx.doi.org/10.1111/j.1600-0463.2008.00871.x PMid:18452424           
  13. Meers S, Lagrou K, Theunissen K et al. Myeloablative conditioning predisposes patients for Toxoplasma gondii reactivation after allogeneic stem cell transplantation. Clin Infect Dis 2010;50:1127-1134. http://dx.doi.org/10.1086/651266 PMid:20218875           
  14. Busemann C, Ribback S, Zimmermann K et al. Toxoplasmosis after allogeneic stem cell transplantation--a single centre experience. Ann Hematol 2012;91:1081-1089. http://dx.doi.org/10.1007/s00277-012-1406-5 PMid:22249208           
  15. Osthoff M, Chew E, Bajel A et al. Disseminated toxoplasmosis after allogeneic stem cell transplantation in a seronegative recipient. Transpl Infect Dis 2013;15:E14-19.      
  16. Montoya JG. Laboratory diagnosis of Toxoplasma gondii infection and toxoplasmosis. J Infect Dis 2002; 185 (Suppl 1): S73-82.       
  17. Ionita C, Wasay M, Balos L, Bakshi R. MR imaging in toxoplasmosis encephalitis after bone marrow transplantation: Paucity of enhancement despite fulminant disease. AJNR Am J Neuroradiol 2004; 25: 270-273. PMid:14970029           
  18. Vidal CI, Pollack M, Uliasz A, del Toro G, Emanuel PO. Cutaneous toxoplasmosis histologically mimicking graft-versus-host disease. Am J Dermatopathol 2008; 30: 492-493. http://dx.doi.org/10.1097/DAD.0b013e3181837952 PMid:18806497           
  19. Beraud G, Pierre-Francois S, Foltzer A et al. Cotrimoxazole for treatment of cerebral toxoplasmosis: An observational cohort study during 1994–2006. Am J Trop Med Hyg 2009; 80: 583-587. PMid:19346380           
  20. Rodriques Coura J, de Castro SL. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 2002; 97: 3-24. http://dx.doi.org/10.1590/S0074-02762002000100001        
  21. Villalba R, Fornés G, Alvarez MA et al. Acute Chagas' disease in a recipient of a bone marrow transplant in Spain: case report. Clin Infect Dis 1992;14:594-595. http://dx.doi.org/10.1093/clinids/14.2.594 PMid:1554849           
  22. Altclas J, Sinagra A, Jaimovich G et al. Reactivation of chronic Chagas' disease following allogeneic bone marrow transplantation and successful pre-emptive therapy with benznidazole. Transpl Infect Dis 1999;1:135-137. http://dx.doi.org/10.1034/j.1399-3062.1999.010207.x PMid:11428981           
  23. Fores R, Sanjuan I, Portero F et al. Chagas disease in a recipient of cord blood transplantation. Bone Marrow Transplant 2007; 39: 127-128. http://dx.doi.org/10.1038/sj.bmt.1705551 PMid:17213850    
  24. Angheben A, Giaconi E, Menconi M et al. Reactivation of Chagas disease after a bone marrow transplant in Italy: first case report. Blood Transfus 2012;10:542-544. PMid:22790268 PMCid:PMC3496236      
  25. Bern C. Chagas disease in the immunosuppressed host. Curr Opin Infect Dis 2012; 25: 450-457. http://dx.doi.org/10.1097/QCO.0b013e328354f179 PMid:22614520           
  26. Le Loup G, Pialoux G, Lescure FX. Update in treatment of Chagas disease. Curr Opin Infect Dis 2011; 24: 428-434. http://dx.doi.org/10.1097/QCO.0b013e32834a667f PMid:21857512           
  27. Pinazo MJ, Miranda B, Rodriguez-Villar C et al. Recommendations for management of Chagas disease in organ and hematopoietic tissue transplantation programs in nonendemic areas. Transplant Rev (Orlando) 2011; 25: 91-101. http://dx.doi.org/10.1016/j.trre.2010.12.002 PMid:21530219           
  28. Molina I, Gómez i Prat J, Salvador F, Trevi-o B, et al. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. N Engl J Med 2014; 370:1899-1908. http://dx.doi.org/10.1056/NEJMoa1313122 PMid:24827034           
  29. Postorino MC, Bellantoni M, Catalano C et al. Visceral leishmaniasis reactivation in transplant patients: A minireview with report of a new case. J Nephrol 2011; 24: 530-534. http://dx.doi.org/10.5301/JN.2011.8343 PMid:21607915           
  30. Sirvent-von Bueltzingsloewen A, Rosenthal MP. Visceral leishmaniasis: a new opportunistic infection in hematopoietic stem-cell transplanted patients. Bone Marrow Transplant 2004;33:667-668. http://dx.doi.org/10.1038/sj.bmt.1704396 PMid:14730334           
  31. Agteresch HJ, van't Veer MB, Cornelissen JJ, Sluiters JF. Visceral leishmaniasis after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2007;40:391-393. http://dx.doi.org/10.1038/sj.bmt.1705728 PMid:17572716           
  32. Bautista G, Ramos A, Gil S. Visceral leishmaniasis in hematopoietic stem cell transplantation. Transpl Int 2012; 25: e83-e85. http://dx.doi.org/10.1111/j.1432-2277.2012.01487.x PMid:22551448           
  33. Martinez-Losada C, Martin C, Cuenca T, Torres A. Duodenal leishmaniasis after allogeneic hematopoietic SCT. Bone Marrow Transplant 2013; 48: 614-615. http://dx.doi.org/10.1038/bmt.2012.190 PMid:23042493            
  34. Komitopoulou A, Tzenou T, Baltadakis J, Apostolidis J, Karakasis D, Harhalakis N.Is leishmaniasis an "unusual" suspect of infection in allogeneic transplantation? Transpl Infect Dis. 2014;16:1012-8. http://dx.doi.org/10.1111/tid.12316 PMid:25412926           
  35. Dantas Brito M, Campilho F, Branca R et al. Visceral leishmaniasis: A differential diagnosis to remember after bone marrow transplantation. Case Rep Hematol 2014;2014:587912. http://dx.doi.org/10.1155/2014/587912        
  36. Miller CE, Bain BJ. The utility of blood and bone marrow films and trephine biopsy sections in the diagnosis of parasitic infections. Mediterr J Hematol Infect Dis 2015;7:e2015039. http://dx.doi.org/10.4084/mjhid.2015.039 PMid:26075046 PMCid:PMC4450651       
  37. Reithinger R, Dujardin JC. Molecular diagnosis of leishmaniasis: Current status and future applications. J Clin Microbiol 2007; 45: 21-25. http://dx.doi.org/10.1128/JCM.02029-06 PMid:17093038 PMCid:PMC1828971       
  38. Vigna E, De Vivo A, Gentile M et al. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompromised patients. Transpl Infect Dis 2010;12:428-431. http://dx.doi.org/10.1111/j.1399-3062.2010.00519.x PMid:20534035          
  39. Jarvis JN, Lockwood DN. Clinical aspects of visceral leishmaniasis in HIV infection.Curr Opin Infect Dis 2013; 26:1-9. http://dx.doi.org/10.1097/QCO.0b013e32835c2198 PMid:23221770           
  40. Cirino CM, Leitman SF, Palmore TN, et al. Transfusion-associated babesiosis with an atypical time course after nonmyeloablative transplantation for sickle cell disease. Ann Intern Med 2008; 148:794-795. http://dx.doi.org/10.7326/0003-4819-148-10-200805200-00018 PMid:18490697 PMCid:PMC3426501      
  41. Lubin AS, Snydman DR, Miller KB. Persistent babesiosis in a stem cell transplant recipient. Leuk Res 2011;35:e77-78. http://dx.doi.org/10.1016/j.leukres.2010.11.029 PMid:21185598 PMCid:PMC3085102       
  42. Kappagoda S, Singh U, Blackburn BG. Antiparasitic therapy. Mayo Clin Proc 2011; 86: 561-583. http://dx.doi.org/10.4065/mcp.2011.0203 PMid:21628620 PMCid:PMC3104918       
  43. Krause PJ, Gewurz BE, Hill D et al. Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis 2008; 46: 370-376. http://dx.doi.org/10.1086/525852 PMid:18181735           
  44. Wormser GP, Prasad A, Neuhaus E et al. Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection. Clin Infect Dis 2010; 50: 381-386. http://dx.doi.org/10.1086/649859 PMid:20047477          
  45. Carroll JF, Benante JP, Kramer M, Lohmeyer KH, Lawrence K. Formulations of deet, picaridin, and IR3535 applied to skin repel nymphs of the lone star tick (Acari: Ixodidae) for 12 hours. J Med Entomol 2010; 47: 699-704. http://dx.doi.org/10.1093/jmedent/47.4.699 PMid:20695288           
  46. Anderlini P, Przepiorka D, Luna M et al. Acanthamoeba meningoencephalitis after bone marrow transplantation. Bone Marrow Transplant 1994;14:459-461. PMid:7994273           
  47. Feingold JM, Abraham J, Bilgrami S et al. Acanthamoeba meningoencephalitis following autologous peripheral stem cell transplantation. Bone Marrow Transplant 1998;22:297-300. http://dx.doi.org/10.1038/sj.bmt.1701320 PMid:9720747           
  48. Castellano-Sanchez A, Popp AC, Nolte FS et al. Acanthamoeba castellani encephalitis following partially mismatched related donor peripheral stem cell transplantation. Transpl Infect Dis 2003;5:191-194. http://dx.doi.org/10.1111/j.1399-3062.2003.00029.x PMid:14987204           
  49. Pemán J, Jarque I, Frasquet J et al. Unexpected postmortem diagnosis of Acanthamoeba meningoencephalitis following allogeneic peripheral blood stem cell transplantation. Am J Transplant 2008;8:1562-1566. http://dx.doi.org/10.1111/j.1600-6143.2008.02270.x PMid:18510635           
  50. Kaul DR, Lowe L, Visvesvara GS, Farmen S, Khaled YA, Yanik GA. Acanthamoeba infection in a patient with chronic graft-versus-host disease occurring during treatment with voriconazole. Transpl Infect Dis 2008;10:437-441. http://dx.doi.org/10.1111/j.1399-3062.2008.00335.x PMid:18713138           
  51. Akpek G, Uslu A, Huebner T et al. Granulomatous amebic encephalitis: an under-recognized cause of infectious mortality after hematopoietic stem cell transplantation. Transpl Infect Dis 2011;13:366-373. http://dx.doi.org/10.1111/j.1399-3062.2011.00612.x PMid:21338461           
  52. Doan N, Rozansky G, Nguyen HS et al. Granulomatous amebic encephalitis following hematopoietic stem cell transplantation. Surg Neurol Int 2015;6 (Suppl 18):S459-462. http://dx.doi.org/10.4103/2152-7806.166788 PMid:26539322 PMCid:PMC4604647      
  53. Marcos LA, Gotuzzo E. Intestinal protozoan infections in the immunocompromised host. Curr Opin Infect Dis 2013;26:295-301. http://dx.doi.org/10.1097/qco.0b013e3283630be3        
  54. Keiser PB, Nutman TB. Strongyloides stercoralis in the immunocompromised population. Clin Microb Rev 2004; 17: 208-217. http://dx.doi.org/10.1128/CMR.17.1.208-217.2004 PMCid:PMC321465       
  55. Orlent H, Crawley C, Cwynarski K, Dina R, Apperley J. Strongyloidiasis pre and post autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2003;32:115-117. http://dx.doi.org/10.1038/sj.bmt.1704104 PMid:12815488           
  56. Schaffel R, Portugal R, Maiolino A, Nucci M. Strongyloidiasis pre and post autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2004;33:117. http://dx.doi.org/10.1038/sj.bmt.1704309 PMid:14704664           
  57. Qazilbash MH, Ueno NT, Hosing C et al. Strongyloidiasis after unrelated nonmyeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2006;38:393-394. http://dx.doi.org/10.1038/sj.bmt.1705448 PMid:16845427           
  58. Wirk B, Wingard JR. Strongyloides stercoralis hyperinfection in hematopoietic stem cell transplantation. Transpl Infect Dis. 2009;11:143-148. http://dx.doi.org/10.1111/j.1399-3062.2008.00360.x PMid:19144095           
  59. Ramanathan R, Nutman T. Strongyloides stercoralis infection in the immunocompromised host. Curr Infect Dis Rep 2008; 10: 105-110. http://dx.doi.org/10.1007/s11908-008-0019-6 PMid:18462583 PMCid:PMC3401551      
  60. Vadlamudi RS, Chi DS, Krishnaswamy G. Intestinal strongyloidiasis and hyperinfection syndrome. Clin Mol Allergy 2006; 4: 8. http://dx.doi.org/10.1186/1476-7961-4-8 PMid:16734908 PMCid:PMC1538622      
  61. Siddiqui AA, Berk SL. Diagnosis of Strongyloides stercoralis infection. Clin Infect Dis 2001; 33: 1040-1047. http://dx.doi.org/10.1086/322707 PMid:11528578           
  62. Schaffel R, Nucci M, Carvalho E, et al. The value of an immunoenzymatic test (enzyme-linked immunosorbent assay) for the diagnosis of strongyloidiasis in patients immunosuppressed by hematologic malignancies. Am J Trop Med Hyg 2001; 65: 346-350. PMid:11693882           
  63. Tarr PE, Miele PS, Peregoy KS, Smith MA, Neva FA, Lucey DR. Case report: Rectal administration of ivermectin to a patient with Strongyloides hyperinfection syndrome. Am J Trop Med Hyg 2003; 68: 453-455. PMid:12875295           
  64. Marty FM, Lowry CM, Rodriguez M et al. Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin. Clin Infect Dis 2005; 41: e5-8. http://dx.doi.org/10.1086/430827 PMid:15937753       

 [TOP]

Abstract views:
953

Views:
PDF
281
HTML
2734

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2016 Mediterranean Journal of Hematology and Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

The Mediterranean Journal of Hematology and Infectious Diseases [eISSN 2035-3006] is owned by the U.C.S.C. and it is published by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS.
 
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185